BeOne Medicines Ltd.ONC
What BeOne Medicines Ltd. does.
We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. In 2025, we generated total global revenue of approximately $5.3 billion, increasing revenue by approximately 40.2% from the prior year, while achieving net income of $286.9 million, net cash provided by operating activities of $1.1 billion and positive free cash flow of $941.7 million.
We are serial innovators in hematology and have built a differentiated, wholly-owned, and foundational franchise. We are the only company with potentially best-in-class assets across three foundational chronic lymphocytic leukemia (“CLL”) mechanisms of action (“MoAs”). This includes BRUKINSA ® , a proven best-in-class Bruton’s tyrosine kinase (“BTK”) inhibitor, sonrotoclax, a next-generation and potentially best-in-class B-cell lymphoma 2 (“BCL2”) inhibitor that received its first global regulatory approval in December 2025, and our potentially first-in-class and best-in-class BTK chimeric degradation activation compound (“BTK-CDAC”).
BRUKINSA was designed for complete sustainable inhibition of BTK with the belief that this would improve patient outcomes. This hypothesis was supported in the ALPINE trial, where BRUKINSA demonstrated sustained superior efficacy and lower cardiac toxicity in an all-comers relapsed/refractory (“R/R”) CLL population against ibrutinib. BRUKINSA is the only BTK inhibitor to prove superior efficacy to ibrutinib, especially over the long term. BRUKINSA has the broadest label in the class, with U.S. approvals in CLL, mantle cell lymphoma (“MCL”), Waldenström’s macroglobulinemia (“WM”), marginal zone lymphoma (“MZL”) and follicular lymphoma (“FL”). Despite being the third entrant to the market, BRUKINSA became the global market leader across B-cell malignancies in 2025. BRUKINSA generated $3.9 billion in sales in 2025, is approved in over 75 markets and has launched in many key markets, including Europe, Japan, Korea and Brazil. Our Phase 3 MANGROVE trial is evaluating BRUKINSA plus rituximab compared with bendamustine plus rituximab in previously untreated MCL. Pending approval, this would be the first chemo-free regimen available for patients as a first line (“1L”) treatment for MCL.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $308.9M | $1.2B | $1.4B | $2.5B | $3.8B | $5.3B |
| Net income | -$1.6B | -$1.5B | -$2.0B | -$881.7M | -$644.8M | $286.9M |
| Free cash flow | -$1.4B | -$1.6B | -$1.8B | -$1.7B | -$633.3M | $941.7M |
More on ONC.
- BeOne Medicines Ltd. summary
- BeOne Medicines Ltd. financial statements
- BeOne Medicines Ltd. key metrics
- BeOne Medicines Ltd. health scores and style box
- BeOne Medicines Ltd. earnings
- BeOne Medicines Ltd. dividends
- BeOne Medicines Ltd. valuation
- BeOne Medicines Ltd. ownership and insiders
- BeOne Medicines Ltd. peers
Figures from BeOne Medicines Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.